Display options
Cite
Zhang X, Brooks B, Molyneaux L, et al. Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity. Int J Endocrinol. 2014;2014:354040doi: 10.1155/2014/354040.
Zhang, X., Brooks, B., Molyneaux, L., Landy, E., Banatwalla, R., Wu, T., Wong, J., Su, B., & Yue, D. K. (2014). Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity. International journal of endocrinology, 2014354040. https://doi.org/10.1155/2014/354040
Zhang, X, et al. "Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity." International journal of endocrinology vol. 2014 (2014): 354040. doi: https://doi.org/10.1155/2014/354040
Zhang X, Brooks B, Molyneaux L, Landy E, Banatwalla R, Wu T, Wong J, Su B, Yue DK. Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity. Int J Endocrinol. 2014;2014:354040. doi: 10.1155/2014/354040. Epub 2014 Aug 10. PMID: 25180036; PMCID: PMC4142741.
Copy Download .nbib Format: NLM
Share it on

Int J Endocrinol. 2014;2014:354040. doi: 10.1155/2014/354040. Epub 2014 Aug 10.

Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity.

International journal of endocrinology

X Zhang, B Brooks, L Molyneaux, E Landy, R Banatwalla, T Wu, J Wong, B Su, D K Yue

Affiliations

  1. Department of Endocrinology and Metabolism, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116027, China.
  2. Diabetes Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia ; School of Nursing, University of Sydney, Sydney, NSW 2006, Australia.
  3. Diabetes Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia ; Discipline of Medicine, University of Sydney, Sydney, NSW 2006, Australia.
  4. Diabetes Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.

PMID: 25180036 PMCID: PMC4142741 DOI: 10.1155/2014/354040

Abstract

Aims. The aim of this study is to examine the efficacy of adding a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with type 2 diabetes inadequately controlled by metformin and sulphonylurea combination treatment. The response of Asian and non-Asian patients to this regimen was also examined. Methods. The medical and computerized records of 80 patients were examined. These patients had baseline HbA1c levels ranging from 7.0 to 12.5% and had a DPP-4 inhibitor add-on therapy for a minimum period of 12 weeks. The primary endpoint was the change in HbA1c level before and after DPP-4 inhibitor treatment. Results. During oral triple therapy, there was a reduction of HbA1c from 8.3% (7.7-8.9) to 7.2% (6.8-7.6) and 26 patients (32.5%) achieved an HbA1c <7%. Poor baseline glycaemic control, lower BMI, and younger age were associated with a better response, but duration of diabetes and gender did not affect outcome. The HbA1c reduction was not different between Asians and non-Asians group [-1.00% (0.6-1.3) vs -0.90% (0.4-1.6)]. Conclusions. DPP-4 inhibitor as a third-line add-on therapy can achieve significant glycaemic improvement in patients with type 2 diabetes inadequately controlled on the combination of metformin and sulphonylurea. The improvement in HbA1c was similar between Asian and non-Asian patients.

References

  1. N Engl J Med. 2002 Oct 24;347(17):1342-9 - PubMed
  2. Diabetes Care. 2004 Jan;27(1):17-20 - PubMed
  3. Diabetes Obes Metab. 2008 Nov;10(11):1047-56 - PubMed
  4. JAMA. 1999 Jun 2;281(21):2005-12 - PubMed
  5. Open Med. 2012 Jun 04;6(2):e62-74 - PubMed
  6. Diabet Med. 2011 Nov;28(11):1352-61 - PubMed
  7. Diabetes Obes Metab. 2007 Sep;9(5):733-45 - PubMed
  8. Diabetes Obes Metab. 2011 Jan;13(1):65-74 - PubMed
  9. Diabetes Obes Metab. 2009 Feb;11(2):167-76 - PubMed
  10. Endocr Pract. 2009 Sep-Oct;15(6):540-59 - PubMed
  11. Diabetes Care. 2009 Jan;32(1):193-203 - PubMed
  12. Diabetes Care. 2008 Dec;31(12):2315-7 - PubMed
  13. Curr Med Res Opin. 2009 Oct;25(10):2401-11 - PubMed
  14. Diabetes Obes Metab. 2014 Oct;16(10):900-9 - PubMed
  15. Diabetologia. 2013 Apr;56(4):696-708 - PubMed
  16. Diabetes Care. 2006 Dec;29(12):2632-7 - PubMed

Publication Types